title: Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs.
authors.affiliation: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. bleeker.jonathan@mayo.edu
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Bleeker
authors.forename: Faisal F
authors.initials: FF
authors.lastname: Syed
authors.forename: Leslie T
authors.initials: LT
authors.lastname: Cooper
authors.forename: Catherine R
authors.initials: CR
authors.lastname: Weiler
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D008231:Lymphopenia / Q000139:chemically induced; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C434107:mepolizumab